

Nouveau Biosciences Appoints Joseph Turgeon as Chief Operating Officer

[New York, NY – September 16, 2025] – Nouveau Biosciences, a biotechnology company pioneering nanomedicine and targeted oncology therapeutics, today announced the appointment of Joseph Turgeon as Chief Operating Officer.

Mr. Turgeon brings more than 38 years of experience in the pharmaceutical and biotechnology industries, with a career distinguished by leadership in oncology drug development, global sales and marketing, and product strategy. He most recently served as President, Chief Executive Officer, and Director of Spectrum Pharmaceuticals, where he successfully guided the company's operations and strategic direction from 2017 to 2021.

Prior to becoming CEO, Mr. Turgeon served as President & Chief Operating Officer (2014–2017) and as Senior Vice President & Chief Commercial Officer (2012–2014) at Spectrum Pharmaceuticals. During his tenure, he played a central role in building Spectrum's commercial and development capabilities, positioning the company as a recognized leader in oncology innovation.

Before joining Spectrum, Mr. Turgeon spent 22 years at Amgen Inc., where he rose to the position of Vice President of Sales. At Amgen, he was instrumental in launching many of the company's most successful drugs across oncology, inflammation, and bone health, and was a key member of the original commercial team that helped establish Amgen as a global leader in biotechnology.

"We are honored to welcome Joe to Nouveau Biosciences," said Owen A. O'Connor, M.D., Ph.D., Chief Executive Officer and Chairman of Nouveau Biosciences. "His deep expertise in oncology drug development and his proven track record of leading organizations through growth and commercialization will be invaluable as we advance our nanomedicine platform into the clinic and prepare for broader strategic partnerships."

As Chief Operating Officer, Mr. Turgeon will oversee all operational aspects of Nouveau Biosciences, including clinical development execution, business operations, and commercial strategy, supporting the company's mission to deliver next-generation cancer therapies to patients worldwide.

"Nouveau Biosciences is built on a vision of transforming oncology care through a scientifically driven platform leading to highly targeted nanomedicines," said Joseph Turgeon. "I am excited to join this dynamic team and leverage my experience to help bring forward therapies that can truly change the standard of care for patients."

About Nouveau Biosciences

Nouveau Biosciences is an innovative biotechnology company that deploys a proprietary platform technology that integrates the latest scientific advances in cancer biology, genomics, computational biology and nanomedicine to produce precision targeted drugs tailored for very specific types of cancer. Its polymer-based nanoparticles are engineered to deliver both individual drugs and optimized combinations with enhanced precision, leading to improved tolerability and efficacy. The company's lead program is clinic-ready, backed by strong intellectual property, and designed to address high-need oncology indications. The technology represents a quantum advance in the generation of highly precision targeted drugs, offering innumerable advances over technologies.

Media Contact

Petrina Whyte

media@nouveaubiosciences.com